SRGN and neoplasm: Our results point either to that the serglycin-deficient lung/liver microenvironment is unsuitable to support colonization and growth of the circulating SG-/- tumour cells or that SG-/- tumour cells cannot extravasate, and that other proteoglycans are unable to compensate for the lack of serglycin in these processes.